Status:
COMPLETED
A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227B
Lead Sponsor:
Addpharma Inc.
Conditions:
Primary Hypertension
Eligibility:
All Genders
19+ years
Phase:
PHASE1
Brief Summary
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-227 in healthy subjects.
Eligibility Criteria
Inclusion
- Body weight equal to or greater than 50kg (Female 45kg) and Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit
- The Age equal to or greater than 19 in healthy volunteers at the time of screening visit
Exclusion
- Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
- Other exclusions applied
Key Trial Info
Start Date :
July 12 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 13 2025
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06884085
Start Date
July 12 2025
End Date
August 13 2025
Last Update
December 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Central Hospital
Seoul, South Korea